CorMedix Inc. CRMD R2K

Healthcare · Biotechnology · United States

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Market & Price

Market Cap

$662.13M

Current Price

$8.44

High / Low (52W)

$16.56 / $6.25

Beta

1.46

Valuation

Stock P/E

3.89

Industry PE

23.65

Forward P/E

24.11

PEG Ratio

Book Value

$5.58

Price to Book

1.51

P/S

1.66

EV/EBITDA

2.76

Dividend Yield

Profitability & Returns

ROCE

23.44%

ROE

65.59%

ROA

26.40%

Profit Margin

45.25%

Op Margin

49.96%

EPS (Latest Qtr)

$0.43

EPS (TTM)

$2.17

Balance Sheet & Liquidity

Debt/Equity

0.34

Quick Ratio

2.58

Current Ratio

2.98

Debt

$147.42M

Total Assets

$826.14M

Current Assets

$367.05M

Working Capital

$192.78M

Ownership

Promoter Holding

7.51%

Chg in Prom Hold

FII / Inst Holding

54.89%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

$631.46M

Total Revenue (TTM)

$400.05M

EBITDA

$228.80M

Free Cash Flow

$119.84M

Operating Cash Flow

$197.69M

Shares Outstanding

78.45M

Gross Margin

91.86%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

1,582.83%

Profit 5Y

216.33%

Revenue (YoY)

226.10%

Earnings (YoY)

42.80%

PROS

Strong return on equity of 65.6%.
Healthy ROCE of 23.4%.
Excellent profit margin of 45.2%.
Compounding revenue at 1582.8% over 5 years.
Profit CAGR of 216.3% over 5 years.
Generates positive free cash flow.

CONS

Trading 49.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CRMD CorMedix Inc. R2K	8.44	3.89	$662.13M	-	23.44%	65.59%	1,582.83%	216.33%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.08M	39.74M	104.28M	128.62M	127.43M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.60M	1.86M	11.19M	21.31M	22.30M
Gross Profit	-14.75K	15.77K	14	18	1	-141	-8.80K	-170.68K	529	36	-54.01K	118.12K	-5.58K	-5.37K	-26.11K	60.08K	-63.26K	14.14K	-19.50K	25.54K	-2.74K	13.11K	26.92K	-6.24K	12.92K	6.11K	20.92K	5.35K	-	-	-	-818.54K	296.28K	10.77M	-	37.48M	37.87M	93.08M	107.31M	105.12M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.36M	18.33M	41.73M	48.18M	41.46M
Operating Income	-1.89M	-1.86M	-3.91K	-4.13K	-4.71K	-3.89K	-4.15M	-4.91M	-9.16M	-6.43K	-7.62M	-7.02M	-8.01M	-10.19M	-8.57M	-10.24M	-4.92M	-5.54M	-5.17M	-5.61M	-8.92M	-6.60M	-7.21M	-5.88M	-8.56M	-7.03M	-8.24M	-6.96M	-11.02M	-11.80M	-10.47M	-16.70M	-15.30M	-3.29M	-	20.12M	19.54M	51.35M	59.13M	63.66M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.29M	20.52M	57.31M	68.70M	74.20M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.01K	10.01K	6.67K	948.24K	1.82M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.64M	20.35M	52.58M	56.45M	55.65M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	521.51K	-55.99M	42.43M	17.04M
Net Income	3.51M	-5.04M	-5.50K	-4.13K	-4.69K	-3.87K	-4.12M	-4.89M	-9.13M	-6.40K	-7.60M	-5.15M	-9.96M	-10.19M	-8.56M	-10.24M	-5.17M	-696.16K	-5.26M	-5.56M	-3.78M	-6.60M	-7.22M	-4.63M	-8.57M	-7.03M	-7.60M	-6.85M	-10.57M	-11.27M	-9.74M	-14.47M	-14.15M	-2.78M	-	20.64M	19.83M	108.56M	14.02M	38.60M
Diluted EPS	-0.05	-	-	-0.13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.12	-0.22	-0.18	-0.19	-0.17	-0.24	-0.25	-0.17	-0.25	-0.25	-0.05	-	0.30	0.28	1.26	0.16	0.43
R&D Expense	171.93K	292.69K	1.24K	1.80K	1.76K	1.49K	2.09M	2.77M	6.84M	4.03K	4.92M	5.09M	6.01M	8.28M	6.60M	8.29M	2.87M	2.98M	2.52M	2.47M	5.69M	2.93M	2.64M	2.52M	4.74M	2.29M	3.21M	2.34M	3.41M	4.79M	2.66M	837.45K	650.99K	727.12K	-	3.19M	2.44M	5.10M	-	7.21M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	0	2.00K	189.27K	210.13K	224.10K	329.33K	429.80K	283.27K	239.23K	190.94K	65.41K	0	43.47M	311.71M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.73K	0	3.19M	35.96M
Gross Profit	-	-	-	-	-	0	-199.60K	-256.52K	-108.59K	-142.57K	214.36K	33.01K	-89.97K	34.38K	42.00K	61.67K	0	40.28M	275.75M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	30.69M	48.96M	62.64M	125.61M
Operating Income	-	-	-	-8.51M	-7.25M	-3.00M	-4.92M	-8.90M	-16.65M	-24.76M	-32.92M	-26.86M	-21.01M	-27.22M	-29.44M	-30.62M	-48.96M	-22.36M	150.14M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30.18M	-46.23M	-18.98M	167.35M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26.52K	34.30K	36.00K	2.78M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-30.29M	-46.34M	-19.32M	150.02M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-585.62K	0	-1.40M	-13.04M
Net Income	-7.24M	-9.00M	-8.12M	-10.91M	-6.71M	-3.38M	-9.13M	-20.45M	-18.19M	-24.64M	-33.01M	-26.83M	-16.43M	-22.03M	-28.21M	-29.70M	-46.34M	-17.93M	163.06M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.75	-0.74	-0.91	-0.30	2.04
R&D Expense	-	-	-	5.49M	4.10M	1.14M	1.23M	1.32M	6.28M	15.74M	24.49M	18.82M	11.05M	13.38M	13.13M	10.68M	13.16M	3.94M	19.33M

Compounded Sales Growth

5 Years:	1,582.83%
1 Year:	226.10%

Compounded Profit Growth

5 Years:	216.33%
1 Year:	42.80%

Stock Price Performance

1 Year:	-30.48%
6 Months:	-10.21%
3 Months:	+18.37%
1 Month:	+12.83%

Balance Sheet (Annual)

Figures in USD.

Metric	Jul 2006	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	8.85M	2.56M	1.15M	2.97M	5.10M	37.10M	21.91M	13.45M	18.83M	29.48M	49.31M	-	62.04M	82.06M	118.85M	826.14M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	59.55M	79.45M	114.58M	367.05M
Cash & Equivalents	0	-	-	-	1.51M	8.28M	1.99M	835.47K	2.37M	4.34M	11.82M	8.06M	10.38M	17.62M	16.35M	41.91M	-	43.15M	43.64M	40.65M	144.84M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2.11M	7.60M	29.72M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	51.65M	171.23M
Total Liabilities	-	-	-	-	-	1.59M	1.32M	1.49M	6.99M	1.46M	3.09M	4.09M	6.26M	13.89M	5.83M	5.09M	-	6.98M	11.92M	34.19M	420.83M
Current Liabilities	-	-	-	-	-	1.58M	1.31M	1.48M	1.67M	1.43M	3.06M	4.09M	6.26M	7.77M	5.83M	4.16M	-	6.31M	11.40M	33.84M	174.27M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	144.63M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	802.43K	667.63K	517.00K	148.91M
Total Equity	-	-966.17K	-4.40M	-12.03M	-14.71M	7.26M	1.24M	-335.38K	-4.02M	3.63M	34.01M	17.81M	7.19M	4.93M	23.65M	44.22M	-	55.06M	70.14M	84.66M	405.31M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	42.82M	54.94M	64.41M	79.26M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-3.67M	-6.30M	-2.28M	-3.62M	-6.32M	-12.53M	-22.27M	-28.59M	-23.70M	-15.05M	-21.97M	-	-24.36M	-38.41M	-50.62M	175.05M
Investing Cash Flow	-10.36K	-1.62K	0	-35.68K	-25.40K	-23.61M	11.42M	10.36M	1.56M	-12.02M	7.43M	-	-3.71M	-17.06M	21.23M	-308.43M
Financing Cash Flow	10.46M	0	1.13M	5.20M	8.36M	43.63M	7.09M	20.52M	29.40M	25.80M	40.10M	-	17.90M	55.92M	26.32M	238.45M
Capital Expenditure	-10.36K	-1.62K	-0	-35.68K	-25.40K	-15.45K	-58.72K	-151.99K	-48.89K	-36.57K	-112.64K	-	-219.36K	-327.30K	-116.00K	-2.26M
Free Cash Flow	-3.68M	-6.30M	-2.28M	-3.65M	-6.35M	-12.54M	-22.32M	-28.74M	-23.75M	-15.09M	-22.08M	-	-24.58M	-38.74M	-50.73M	172.79M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-10.17M	445.64K	-3.06M	105.07M

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-9,975.2%	-135.5%	-51.7%	-63.6%	65.1%	7.7%	-31.8%	14.4%	22.0%	94.3%	-	92.7%	88.5%
Operating Margin %	-	-	-	-	-	-	-245,646.9%	-4,703.3%	-7,925.6%	-11,048.8%	-9,997.4%	-6,250.4%	-7,416.3%	-11,378.4%	-15,417.5%	-46,819.9%	-	-51.4%	48.2%
Net Margin %	-	-	-	-	-	-	-456,426.7%	-10,806.3%	-8,655.4%	-10,996.5%	-10,023.4%	-6,242.4%	-5,801.3%	-9,207.7%	-14,774.7%	-45,409.9%	-	-41.2%	52.3%
ROE %	164.6%	74.8%	55.2%	-150.3%	-542.8%	1,008.0%	227.1%	-562.8%	-53.5%	-138.3%	-458.9%	-543.7%	-69.5%	-49.8%	-	-53.9%	-66.1%	-21.2%	40.2%
ROCE %	-	-	-	-117.0%	-579.3%	928.2%	-379.9%	-242.4%	-48.9%	-139.0%	-457.7%	-242.9%	-88.8%	-60.3%	-	-55.0%	-69.3%	-26.3%	23.0%

Shareholding Pattern

Insiders

7.51%

Institutions

54.89%

Public Float

59.34%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Deep Track Capital, Lp	8.00%	6.27M	$52.95M
2	Blackrock Inc.	7.61%	5.97M	$50.37M
3	Vanguard Capital Management LLC	3.99%	3.13M	$26.41M
4	State Street Corporation	2.79%	2.19M	$18.50M
5	Royce & Associates LP	2.41%	1.89M	$15.93M
6	Geode Capital Management, LLC	2.32%	1.82M	$15.33M
7	UBS Group AG	1.96%	1.54M	$12.98M
8	Oberweis Asset Management Inc.	1.54%	1.21M	$10.22M
9	Alyeska Investment Group, L.p.	1.08%	850.00K	$7.17M
10	Vanguard Portfolio Management LLC	0.95%	742.57K	$6.27M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CRMD

No recent headlines available.

CRMD · Healthcare

CorMedix Inc.

About

Key Facts

Sector	Healthcare
Industry	Biotechnology
Headquarters	United States
Employees	191
Website	https://cormedix.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

CorMedix Inc. CRMD R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More